Quality of Life, Treatments, and Patients' Willingness to Pay for a Complete Remission of Cervical Cancer in Taiwan

Lang, Hui Chu; Chang, Koyin; Ying, Yung Hsiang

doi:10.1002/hec.1786

Cited by 24 publications

(23 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For VSL-RP, we selected (1) a VSL estimate currently in use by the US Department of Transportation (‘USDoT’) [47], which is very similar to that adopted by the US Department of Health and Human Services [14] and the US Environmental Protection Agency [15], as well as the estimated means from a meta-regression analysis, which adjusted for publication bias [48], and (2) a range of VSL for cancer risk reduction estimated based on hedonic housing prices in the US (‘Gayer 1–2’) [49]. For VSL-SP, we selected VSL estimates from (1) a WTP study conducted among cervical cancer patients in Taiwan (‘Lang’) [50], (2) a recent systematic review of VSL focusing on a ‘cancer premium’ (‘Viscusi’) [45], (3) recommendation of the UK Health and Safety Executive (‘UKHSE’) [13], and (4) OECD guidelines for EU-27 countries (‘OECD’) [44]. All VSL estimates were converted to the current UK currency based on the OECD guideline [44].…”

Section: Methodsmentioning

confidence: 99%

Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks

Park

Jit

2018

BMC Med

View full text Add to dashboard Cite

BackgroundThere is increasing interest in estimating the broader benefits of public health interventions beyond those captured in traditional cost-utility analyses. Cost-benefit analysis (CBA) in principle offers a way to capture such benefits, but a wide variety of methods have been used to monetise benefits in CBAs.MethodsTo understand the implications of different CBA approaches for capturing and monetising benefits and their potential impact on public health decision-making, we conducted a CBA of human papillomavirus (HPV) vaccination in the United Kingdom using eight methods for monetising health and economic benefits, valuing productivity loss using either (1) the human capital or (2) the friction cost method, including the value of unpaid work in (3) human capital or (4) friction cost approaches, (5) adjusting for hard-to-fill vacancies in the labour market, (6) using the value of a statistical life, (7) monetising quality-adjusted life years and (8) including both productivity losses and monetised quality-adjusted life years. A previously described transmission dynamic model was used to project the impact of vaccination on cervical cancer outcomes. Probabilistic sensitivity analysis was conducted to capture uncertainty in epidemiologic and economic parameters.ResultsTotal benefits of vaccination varied by more than 20-fold (£0.6–12.4 billion) across the approaches. The threshold vaccine cost (maximum vaccine cost at which HPV vaccination has a benefit-to-cost ratio above one) ranged from £69 (95% CI £56–£84) to £1417 (£1291–£1541).ConclusionsApplying different approaches to monetise benefits in CBA can lead to widely varying outcomes on public health interventions such as vaccination. Use of CBA to inform priority setting in public health will require greater convergence around appropriate methodology to achieve consistency and comparability across different studies.Electronic supplementary materialThe online version of this article (10.1186/s12916-018-1130-7) contains supplementary material, which is available to authorized users.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks

Park

Jit

2018

BMC Med

View full text Add to dashboard Cite

show abstract

“…Many studies of QOL have been conducted (Lang et al, 2012). For example, studies have used QOL in comparisons of patients before and after cytology-based screening (Korfage et al, 2012), as evaluated using a disease-specific module (Singer et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Health-related Quality of Life for Hypothesized Medical States Associated with Cervical Cancer

Murasawa¹,

Konno²,

Okubo³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“… If, however, the individual is already under treatment for cancer, then a different approach is warranted, as in Lang et al ().…”

mentioning

confidence: 99%

Assessing Whether There Is a Cancer Premium for the Value of a Statistical Life

2013

View full text Add to dashboard Cite

This article estimates whether there is a cancer risk premium for the value of a statistical life using stated preference valuations of cancer risks for a large, nationally representative US sample. The present value of an expected cancer case that occurs after a one decade latency period is $10.85m, consistent with a cancer premium that is 21% greater than the median value of a statistical life estimates for acute fatalities. This cancer premium is smaller than the premium proposed for policy analyses in the UK and the USA. There is also a greater premium for policies that reduce cancer risks to zero and for risk reductions affecting those who perceive themselves to have a greater than average probability of having cancer.

show abstract

Quality of Life, Treatments, and Patients' Willingness to Pay for a Complete Remission of Cervical Cancer in Taiwan

Cited by 24 publications

References 38 publications

Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks

Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks

Evaluation of Health-related Quality of Life for Hypothesized Medical States Associated with Cervical Cancer

Assessing Whether There Is a Cancer Premium for the Value of a Statistical Life

Contact Info

Product

Resources

About